TOCILIZUMAB

tocilizumab 400 mg/20 mL injection, 20 mL vial

TOCILIZUMAB (12810F)

tocilizumab 400 mg/20 mL injection, 20 mL vial
12810F
Body System:
Manner of administration:Injection
Private
S100 HSD Private
Authority Required

Restriction

Indication: Severe active juvenile idiopathic arthritis
Treatment phase: Initial treatment - Initial 4 (Temporary listing - change of treatment from another biological medicine to tocilizumab after resolution of the critical shortage of tocilizumab)

Restriction

Indication: Severe active juvenile idiopathic arthritis
Treatment phase: Initial treatment - Initial 4 (Temporary listing - change of treatment from another biological medicine to tocilzumab after resolution of the critical shortage of tocilizumab)
Quantities & Cost
Max qty packs Max qty units # of repeats DPMQ Max safety net General Patient Charge
Max qty packs: 1 Max qty units: 1 # of repeats: 0 DPMQ: $424.61 Max safety net: $25.00 General Patient Charge: $25.00
Available brands
Actemra
Avtozma